Thryv Therapeutics secures $30 million in Series B financing to advance THRV-1268 into the ASPIRE-HF Phase 2a heart failure study and progress its Long QT Syndrome programme.
Written By: Creola Gonsalves, MS Biotech
Reviewed By: Pharmacally Editorial Team
Thryv Therapeutics has secured $30 million in Series B financing to advance its lead candidate, THRV-1268, into a Phase 2a heart failure study. The announcement coincides with completion of enrollment in the first efficacy cohort of the company’s Wave II Phase 2/3 study in Long QT Syndrome (LQTS), marking progress across two cardiovascular development programmes.
The funding will support ASPIRE-HF, which will evaluate THRV-1268 in adults with symptomatic heart failure with reduced ejection fraction (HFrEF) and QTc prolongation. Enrollment is expected to begin in early 2027. The company also reported a favourable review of available Wave II data by its Independent Data Monitoring Committee (IDMC), with initial efficacy cohort data expected in early 2027.
ASPIRE-HF: Evaluating THRV-1268 in Heart Failure
ASPIRE-HF (Addressing SGK1-driven Prolonged QT and Impaired REmodeling in Heart Failure) is a Phase 2a, double-blind, randomized, placebo-controlled study in adults with symptomatic HFrEF and QTc prolongation who are receiving guideline-directed medical therapy (GDMT).
Participants will be randomized to receive one of two dose levels of THRV-1268 or placebo over a 24-week treatment period. The study will evaluate safety and pharmacokinetics, alongside changes in markers of arrhythmic risk, cardiac function and cardiac remodelling. A prespecified early efficacy assessment will take place at Week 6.
The programme builds on the company’s research into serum glucocorticoid inducible kinase 1 (SGK1), a signalling pathway implicated in cardiac electrical and structural remodelling. According to Thryv, human genetic and preclinical evidence, together with Phase 1 findings demonstrating QT interval shortening in obese individuals, supported the decision to expand THRV-1268 development into heart failure.
For patients with HFrEF and prolonged QTc, electrical instability represents an additional clinical concern alongside progressive cardiac dysfunction. Thryv is investigating whether SGK1 inhibition could address aspects of both electrical and structural cardiac abnormalities. However, the potential clinical benefits in HFrEF remain to be established through controlled clinical studies.
Wave II Long QT Syndrome Study Advances
Alongside the planned heart failure programme, Thryv reported progress in its Wave II Phase 2/3 study of THRV-1268 in Long QT Syndrome (NCT07277582).
The study has completed enrollment of its first efficacy cohort, with data expected in early 2027. During the third quarter of 2026, the IDMC reviewed available safety and pharmacokinetic data and recommended that the study continue without modification. The company also reported that no serious adverse events had been observed.
Thryv has submitted a protocol amendment to its US Food and Drug Administration (FDA) Investigational New Drug (IND) application to include patients with Long QT Syndrome Type 3 (LQT3). The study is now open to participants aged 15 years and older. The amendment’s submission should not be interpreted as confirmation of FDA approval.
Scientific Presentations at AHA 2026
Thryv will present additional research at the American Heart Association (AHA) Scientific Sessions 2026, scheduled for November 6–9 in Chicago, Illinois.
The late-breaking basic science presentation, SGK1 Inhibition, Monotherapy or In Combination With Incretin Agonism, Targets Residual Risk in Cardiometabolic Heart Failure, will examine the potential role of SGK1 inhibition in cardiometabolic heart failure.
A separate poster presentation will report initial findings from the myQTwave national survey, examining the lived experience and symptom burden of patients with Long QT Syndrome Types 2 and 3.
Financing and Strategic Investment
The $30 million Series B financing was led by InClin, Inc., a global contract research organization with operations in San Mateo, California, and Sydney, Australia. Existing investors also participated in the round, including Fonds de solidarité FTQ, Amplitude Ventures, Investissement Québec, Lumira Ventures, adMare BioInnovations, CTI Life Sciences Fund and Alexandria Venture Investments.
InClin joins Thryv as both a strategic investor and clinical operations partner. The companies have worked together in recent months to establish clinical operations in Australia, supporting the planned initiation of ASPIRE-HF.
The proceeds will support the Phase 2a programme through a prespecified safety and efficacy analysis, including assessments of QTc changes and established biomarkers of heart failure risk.
Clinical Development Outlook
The financing supports Thryv’s strategy to evaluate THRV-1268 across two cardiovascular disease settings. While Wave II continues to assess the candidate in Long QT Syndrome, ASPIRE-HF will investigate its potential in HFrEF patients with QTc prolongation.
The expansion represents an important clinical development milestone for the company’s SGK1 inhibition programme. However, the therapeutic relevance of this approach in heart failure will depend on the safety and efficacy findings from ASPIRE-HF, while the upcoming Wave II data will provide further evidence on THRV-1268 in Long QT Syndrome.
Reference
Thryv Therapeutics Announces $30 Million Financing to Launch the ASPIRE-HF Study in Patients with Heart Failure; Wave II Efficacy Cohort Fully Enrolled in Long QT Syndrome, Thryv Therapeutics, 03 November 2026
About the Writer
Creola Gonsalves (Linkedin) is an M.S. Biotechnology postgraduate with a strong interest in clinical research, evidence interpretation, and healthcare writing, with a focus on translating life-science knowledge into meaningful real-world insights.
She is trained in Good Clinical Practice (GCP), clinical research principles, and critical interpretation of randomized clinical trials, with certifications from NIH and Stanford University.
Her research background in biotechnological applications and microbial research strengthens her ability to understand scientific evidence and develop clear, accurate, and research-driven healthcare content.